肝脂肪变对病毒学静止期慢性乙型肝炎纤维化进展和功能性治愈的不同影响
研究前瞻性纳入330例未治疗、丙氨酸氨基转移酶正常且低病毒载量的慢性乙型肝炎患者,基线和3年行瞬时弹性成像评估。肝脂肪变与HBsAg清除率显著升高相关(HR 3.246),但持续重度肝脂肪变独立关联纤维化进展(OR 2.379)。CAP测量对病毒学静止期CHB患者有预测价值。
要点
- 肝脂肪变与HBsAg清除率显著升高相关(HR 3.246,95%CI 1.278-8.243,p=0.013)。
- 持续重度肝脂肪变独立关联纤维化进展(OR 2.379,95%CI 1.231-4.597,p=0.01)。
- CAP测量对病毒学静止期CHB患者有预测价值,常规床旁评估肝脂肪含量重要。
核心结论
- CAP测量对病毒学静止期CHB患者有预测价值。
- 肝脂肪变与纤维化进展风险升高相关,但 paradoxically 与HBsAg清除率3倍升高相关。
- 持续重度肝脂肪变独立关联纤维化进展。
研究设计与样本
- 前瞻性招募未治疗、丙氨酸氨基转移酶正常且低病毒载量(血清HBV DNA <2,000 IU/ml)的CHB患者,行基线和3年瞬时弹性成像评估。
- 纤维化分期按EASL-ALEH指南定义,纤维化进展定义为纤维化分期增加≥1级。
- 肝脂肪变和重度肝脂肪变分别定义为受控衰减参数(CAP)≥248 dB/m和≥280 dB/m。
- 共纳入330例患者(中位年龄50.5岁,男性41.2%,中位HBV DNA 189 IU/ml)。
主要发现
- 随访期间22例患者(6.7%)实现HBsAg清除,肝脂肪变与HBsAg清除率显著升高相关(HR 3.246;95%CI 1.278-8.243;p=0.013)。
- 基线时48.8%和28.8%的患者分别有肝脂肪变和重度肝脂肪变,4.2%有F3/F4纤维化,3年时增至8.7%。
- 持续重度肝脂肪变患者肝纤维化进展率高于无肝脂肪变患者(41.3% vs. 23%;p=0.05)。
- 持续重度肝脂肪变独立关联纤维化进展(OR 2.379;95%CI 1.231-4.597;p=0.01)。
关键数值与推荐
- 肝脂肪变定义为CAP ≥248 dB/m,重度肝脂肪变定义为CAP ≥280 dB/m。
- 纤维化进展定义为纤维化分期增加≥1级(按EASL-ALEH指南)。
- 低病毒载量定义为血清HBV DNA <2,000 IU/ml。
临床怎么用
- 常规床旁评估肝脂肪含量对未治疗CHB患者的风险评估重要。
- CAP测量对病毒学静止期CHB患者有预测价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Concomitant non-alcoholic fatty liver disease is common in patients with chronic hepatitis B (CHB) infection, although its impact on liver-related outcomes remains controversial. We aimed to study the effect of hepatic steatosis on the risk of fibrosis progression and the likelihood of HBsAg seroclearance. METHODS: Treatment-naïve patients with CHB, normal alanine aminotransferase and low viraemia (serum HBV DNA <2,000 IU/ml) were prospectively recruited for baseline and 3-year transient elastography assessment. Fibrosis staging was defined according to the EASL-ALEH guidelines, with fibrosis progression defined as ≥1 stage increment of fibrosis. Hepatic steatosis and severe hepatic steatosis were defined as controlled attenuation parameter (CAP) ≥248 dB/m and ≥280 dB/m, respectively. RESULTS: A total of 330 patients (median age 50.5 years, 41.2% male, median HBV DNA 189 IU/ml) were recruited. Twenty-two patients (6.7%) achieved HBsAg seroclearance during follow-up, and the presence of hepatic steatosis was associated with a significantly higher chance of HBsAg seroclearance (hazard ratio 3.246; 95% CI 1.278-8.243; p = 0.013). At baseline, 48.8% and 28.8% of patients had steatosis and severe steatosis, respectively, while 4.2% had F3/F4 fibrosis at baseline, increasing to 8.7% at 3 years. The rate of liver fibrosis progression in patients with persistent severe steatosis was higher than in those without steatosis (41.3% vs. 23%; p = 0.05). Persistent severe hepatic steatosis was independently associated with fibrosis progression (odds ratio 2.379; 95% CI 1.231-4.597; p = 0.01). CONCLUSIONS: CAP measurements have predictive value in patients with virologically quiescent CHB. The presence of hepatic steatosis was associated with a higher risk of fibrosis progression but, paradoxically, a 3-fold increase in HBsAg seroclearance rate. LAY SUMMARY: Co-existing fatty liver disease in patients with chronic viral hepatitis B infection leads to worsening liver fibrosis, but also increases the chance of cure from hepatitis B virus. Routine bedside assessment of liver fat content is important for risk assessment in treatment-naïve patients with chronic hepatitis B.
引用
- Mak LY, Hui RW, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020. PMID: 32504663. doi:10.1016/j.jhep.2020.05.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。